Jagsonpal Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹74Cr
- −1.3% YoY
- −2.6% QoQ
- Net profit
- ₹13Cr
- +18.2% YoY
- +18.2% QoQ
- Margin
- 22%
- 0 pp YoY
- +3 pp QoQ
Guidance rank: #54 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Jagsonpal Pharmaceuticals Ltd Q2 FY26 key numbers
- Revenue
- Growth has moderated recently due to strategic underperformance of a key product, Dydrogesterone, which dropped from Rs.40 crore to Rs.10 crore in 24 months.
As stated in Jagsonpal Pharmaceuticals Ltd's Q2 FY26 earnings call transcript · published 15 Jul 2026. Reported figures, not investment advice.
The short version
Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year. Jagsonpal Pharmaceuticals targets about 10% overall revenue growth for the current fiscal year, with expectations of accelerated growth thereafter (Page 12).
From Jagsonpal Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year.
- There is an expectation of accelerated growth beyond the current year, with more detailed guidance to be provided in the coming weeks.
- These will contribute to future growth.
- Growth has moderated recently due to strategic underperformance of a key product, Dydrogesterone, which dropped from Rs.40 crore to Rs.10 crore in 24 months.
- The company will focus on launching products in more difficult categories requiring concept selling, aiming for slower but sustainable growth.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The management highlighted cautious new product launches, focusing on less crowded, difficult categories requiring concept selling for sustainable buildup rather than quick scale.
- There is openness to inorganic growth via acquisitions, with funding capacity through cash reserves (~Rs.150 crores), quarterly cash flow (approx. Rs.15 crores), leveraging the balance sheet, and shareholder backing.
- They prefer acquisitions within a moderate size, smaller than large peers like Torrent, but are confident to take bigger acquisition steps due to improved organizational capability.
- The acquisition of Yash Pharma is cited as a successful strategic integration, boosting both growth and margins.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Jagsonpal Pharmaceuticals Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 74 | 75 | -1.3% | 76 | -2.6% |
| Operating profit (EBITDA) | 16 | 16 | 0% | 14 | +14.3% |
| Operating margin | 22% | 22% | 0 pp | 19% | +3 pp |
| Profit before tax | 17 | 15 | +13.3% | 14 | +21.4% |
| Net profit (PAT) | 13 | 11 | +18.2% | 11 | +18.2% |
| EPS (₹) | 1.89 | 1.73 | +9.2% | 1.62 | +16.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharma's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q2 FY26 results?
Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year. Jagsonpal Pharmaceuticals targets about 10% overall revenue growth for the current fiscal year, with expectations of accelerated growth thereafter (Page 12).
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
- The management highlighted cautious new product launches, focusing on less crowded, difficult categories requiring concept selling for sustainable buildup rather than quick scale. - There is openness to inorganic growth via acquisitions, with funding capacity through cash reserves (~Rs.150 crores), quarterly cash flow (approx.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
